Paragon Biosciences stands at the forefront of cutting-edge bioscience and life sciences innovation. Led by founder and CEO Jeff Aronin, the company is committed to accelerating life science innovation using biology breakthroughs to treat and cure diseases. Among its portfolio companies are Emalex Biosciences, CiRC Biosciences and Evozyne.
Emalex Biosciences is currently investigating a therapy to help people living with Tourette Syndrome, a neurological disorder that is characterized by motor and vocal tics. This disorder has few medicines available, leaving patients with unmet medical needs.
CiRC Biosciences is focused on regenerative medicine, specifically for degenerative retinal diseases. The company is pursuing a cell therapy treatment to restore vision for those with retinitis pigmentosa, an inherited eye disease that leads to blindness.
Evozyne creates novel protein systems that enable a healthier world. Built by Paragon Biosciences, Evozyne seeks to solve longstanding challenges in therapeutics and sustainability.
These companies highlight just a few examples of how Jeff Aronin and his team of experts in the industry are making a meaningful impact in life sciences. Paragon Biosciences is aggressively accelerating biology-based innovation to help meet the needs of underserved patients.
